SUMOylation inhibition enhances dexamethasone sensitivity in multiple myeloma

Abstract excerpt

BACKGROUND: Multiple myeloma (MM) is an incurable plasma cell malignancy. Although Dexamethasone (Dex) is the most widely used therapeutic drug in MM treatment, patients develop Dex resistance leading to progressive disease, demanding an urgent need to investigate the mechanisms driving Dex resistance and develop new reagents to address this problem. We propose SUMOylation as a potential mechanism regulating Dex...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Immunotherapy and Immune Responses
• Share to Multiple Myeloma Research and Treatments
• Share to Ubiquitin and proteasome pathways